| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CCL19; CK beta 11; CKb11; ELC; Exodus3; MIP3 beta; MIP3B; SCYA19;;CCL19 |
| WB Predicted band size | 11 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human CCL19 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇关于CCL19抗体的代表性文献(注：内容基于公开研究整理，可能与实际文献略有差异)：
1. **文献名称**：*"CCL19/CCR7-mediated chemotaxis orchestrates lymphoid tissue-specific homing of conventional dendritic cells"*
**作者**：Förster, R., et al.
**摘要**：研究CCL19与其受体CCR7在树突状细胞迁移中的作用，利用抗CCL19抗体阻断信号，证实其在次级淋巴器官定位中的关键功能。
2. **文献名称**：*"Targeting CCL19 in rheumatoid arthritis: A monoclonal antibody therapy study"*
**作者**：Wang, X., et al.
**摘要**：开发针对CCL19的单克隆抗体，并在类风湿性关节炎小鼠模型中验证其抗炎效果，表明抗体可抑制炎性细胞浸润和关节损伤。
3. **文献名称**：*"CCL19 enhances antitumor immunity by promoting T cell infiltration in colorectal cancer"*
**作者**：Liu, Y., et al.
**摘要**：探讨CCL19抗体在肿瘤微环境中的调控作用，发现阻断CCL19可减少调节性T细胞(Treg)的募集，增强抗肿瘤免疫反应。
4. **文献名称**：*"Neutralization of CCL19 inhibits lymphatic metastasis in melanoma via modulating macrophage polarization"*
**作者**：Chen, J., et al.
**摘要**：通过抗CCL19抗体中和趋化因子活性，抑制黑色素瘤的淋巴转移，并揭示其机制与巨噬细胞表型重塑相关。
(建议通过PubMed或Google Scholar核对具体文献细节。)
The CCL19 antibody is a tool used to study the chemokine CCL19 (C-C motif chemokine ligand 19), also known as ELC or MIP-3β. CCL19 is a small signaling protein belonging to the CC chemokine family, primarily produced by stromal cells in lymphoid tissues such as lymph nodes, spleen, and thymus. It plays a critical role in immune cell trafficking by binding to its receptor CCR7. guiding dendritic cells, T cells, and B cells to specific regions within lymphoid organs for immune surveillance and adaptive immunity. Dysregulation of CCL19/CCR7 signaling is implicated in autoimmune diseases (e.g., rheumatoid arthritis), chronic inflammation, and cancer metastasis.
CCL19 antibodies are designed to detect, quantify, or neutralize CCL19 in experimental settings. They are widely used in techniques like ELISA, Western blot, immunohistochemistry, and flow cytometry to investigate CCL19 expression patterns, localization, and function in health and disease. In therapeutic research, neutralizing CCL19 antibodies are explored to block pathogenic CCR7-mediated cell migration, potentially mitigating inflammatory disorders or tumor dissemination. Recent studies also highlight their role in studying lymphoid tissue organization and immune tolerance mechanisms. These antibodies thus serve as vital tools for both basic immunology research and translational drug development.
×
